Abstract
Cardiovascular genomic consists
in the identification of polymorphic genes
responsible for the susceptibility to
cardiovascular disease including coronary
artery disease (CAD). Genes involved in
platelet activation and aggregation play a
key role in the predisposition to CAD. A
considerable inter-variability of platelet
response to agonists and to drugs exists and
in particular the hyper-reactivity phenotype
seems to be heritable. Besides glycoproteins
and receptors expressed on platelets surface
whose mutations significantly impact on
platelet function, moreover researchers in the
last decades have paid great attention to the
genes involved in the response to anti-platelet
drugs, considering their pivotal role in the
treatment and outcomes of CAD patients
especially those undergoing PCI